Human papillomavirus vaccine may reduce the rate of oral HPV infections in young adults by as much as 88 percent, studies suggest. However, given the vaccine’s low rate of uptake in the U.S.—especially in males—the impact of the vaccine on oral HPV infections remains low.
The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.
